1 Antimalarials in mosquitoes overcome *Anopheles* and *Plasmodium* resistance to malaria 2 control strategies

3 Douglas G. Paton^{1*}, Alexandra S. Probst¹, Erica Ma¹, Kelsey L. Adams¹, W. Robert Shaw¹, Naresh
4 Singh¹, Selina Bopp¹, Sarah K. Volkman¹, Domombebe F. S. Hien², Rakiswendé S. Yerbanga², Thierry
5 Lefèvre^{3,4,5}, Abdoullaye Diabaté², Roch K. Dabiré², Dyann F. Wirth¹, Flaminia Catteruccia^{1*}

6

7 ¹ Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health,
8 Boston, USA.

9 ² Institut de Recherche en Sciences de la Santé/Centre Muraz, Bobo-Dioulasso, Burkina Faso

10 ³ MIVEGEC, IRD, CNRS, University of Montpellier, Montpellier, France

11 ⁴ Laboratoire mixte international sur les vecteurs (LAMIVECT), Bobo Dioulasso, Burkina Faso

12 ⁵ Centre de Recherche en Écologie et Évolution de la Santé (CREES), Montpellier, France

13 *Corresponding Authors. Email: fcatter@hsph.harvard.edu, dpaton@hsph.harvard.edu

14 **Abstract**

15 The spread of insecticide resistance in *Anopheles* mosquitoes and drug resistance in malaria parasites
 16 is contributing to a global resurgence of malaria, and the generation of control tools that can overcome
 17 these issues is an urgent public health priority. We recently demonstrated that the transmission of
 18 *Plasmodium falciparum* parasites by *Anopheles gambiae* can be efficiently blocked when female
 19 mosquitoes contact the antimalarial atovaquone deposited on a treated surface, with no negative
 20 consequences on mosquito fitness. Here, we demonstrate that the transmission-blocking efficacy of
 21 mosquito-targeted atovaquone is maintained when highly insecticide resistant, field-derived *Anopheles*
 22 mosquitoes are exposed to this antimalarial, indicating that insecticide resistance mechanisms do not
 23 interfere with drug function. Moreover, this approach prevents transmission of field *P. falciparum*
 24 isolates, including an artemisinin resistant *Kelch13* C580Y mutant, demonstrating that this strategy
 25 could prevent the spread of parasite mutations that induce resistance to front-line antimalarials. Finally,
 26 we show that ingestion of atovaquone in sugar solution is highly effective at limiting parasite
 27 development, including in ongoing infections. These data support the use of mosquito-targeted
 28 antimalarial interventions to potentiate and extend the efficacy of our best malaria control tools.

Introduction

Human malaria, a parasitic disease caused by unicellular eukaryotic *Plasmodium* parasites and spread through the bite of *Anopheles* mosquitoes, remains a substantial cause of global morbidity and mortality (1). Malaria control programs rely on preventative measures focused on mosquito control and on therapeutic measures based on the use of antimalarial drugs. Mosquito control is the most effective tool at reducing the transmission of *Plasmodium* parasites, with long-lasting insecticide-impregnated nets (LLINs) and indoor residuals spraying (IRS) as primary tools for malaria prevention. LLINs alone are predicted to have contributed to 68% of malaria cases averted between 2000 and 2015 (2). Alongside mosquito-targeted preventative interventions, artemisinin combination therapies (ACT) have been the cornerstone of human malaria treatment since their widespread introduction at the beginning of this century (3, 4) and have similarly contributed substantially to the reduction in malaria mortality and morbidity observed since then (2).

Despite sizeable investment, malaria control and elimination efforts are, however, faltering due to reduced operational effectiveness of these key control tools, largely caused by mosquito resistance to insecticides and parasite resistance to drugs (5-7). As pyrethroids are the sole class of insecticides currently approved for use as the primary insecticidal ingredient of LLINs, resistance to insecticides from this group, such as permethrin or deltamethrin, has spread rapidly across sub-Saharan Africa. In the malaria hyperendemic regions of southern Mali and southwest Burkina Faso, for example, resistance to pyrethroids is extreme (8), driven by multifactorial and synergistic resistance mechanisms (9) including reduced insecticide sensitivity through mutation in the target enzyme binding pocket, enhanced metabolic detoxification through upregulated cytochrome P450s, and reduced tarsal uptake through cuticular thickening (10-12). Such levels of insecticide resistance are likely one of the key factors contributing to the recent plateau in malaria incidence in Africa following its steady reduction over the preceding years (1).

Similarly, resistance to ACTs has emerged in *P. falciparum* parasites in Cambodia and other areas of the Greater Mekong subregion (GMS)(13). Mediated through mutations in *kelch13* (*PfK13*) (14), artemisinin resistance has the primary effect of increasing the treatment time required to clear a patient of *Plasmodium* parasites, with a secondary effect of increasing the likelihood of resistance evolving to artemisinin partner drugs such as piperaquine and lumefantrine (15). The emergence and spread of artemisinin resistance to sub-Saharan Africa — a region where as many as 93% of annual malaria deaths occur (1) — is a major concern. Until recently, resistance to these first-line antimalarials was limited geographically to the GMS, however *de novo* *PfK13* mutations associated with *in vitro* resistance have now been detected in both Tanzania and Rwanda (16, 17). Of further concern is the recent invasion and spread of the Asian vector *Anopheles stephensi* to the horn of Africa (18), as this mosquito species is highly competent for the transmission of *P. falciparum* parasites endemic to the GMS and invasive populations may facilitate the spread of parasites harboring resistance mutations from Asia to Africa.

A control strategy that blocks the transmission of malaria parasites, including those carrying drug-resistant mutations, without imposing strong selective pressure on mosquitoes or parasites could overcome the limitations of current interventions, providing a critical addition to the malaria elimination toolkit. In an effort to generate such a strategy, we recently demonstrated that transmission of *P. falciparum* parasites can be prevented when *Anopheles gambiae* mosquitoes, a major malaria vector in sub-Saharan Africa, are exposed to the antimalarial drug atovaquone (ATQ), a potent cytochrome bc1 inhibitor (19). Exposure through direct contact between the compound and the mosquito tarsi (lower legs) — analogous to the mode of insecticide exposure on LLINs or IRS — completely abrogated parasite development when it occurred around the time of infection (between 24 h before a *P. falciparum*-infected blood meal (IBM) and 12 h post IBM). Tarsal exposure to ATQ killed parasites within the midgut lumen prior to ookinete formation and was not associated with any harmful effect on the mosquito. These results demonstrate that, unlike with the use of insecticides,

78 there would be no selective pressure leading to mosquito resistance to direct antimalarial exposure.
 79 Importantly, incorporating these data in a mathematical model of malaria transmission showed that
 80 parasite prevalence in the human population in sub-Saharan Africa would be remarkably decreased by
 81 the incorporation of antimalarials on LLINs (19). In field settings, however, antimalarials on LLINs
 82 or IRS must maintain efficacy when absorbed by insecticide-resistant mosquitoes, as resistance
 83 mechanisms may interfere with drug efficacy. Furthermore, they must be active against *P. falciparum*
 84 strains circulating in endemic regions, including parasites carrying resistance-conferring mutation. In
 85 the latter case, the use of antimalarials on LLINs or IRS could also be exploited to slow or prevent the
 86 spread of drug-resistance haplotypes by specifically targeting parasites at a severe bottleneck in the
 87 malaria transmission cycle, where typically less than 100 ookinetes escape the mosquito midgut lumen
 88 to form oocysts (20-22). It is important to stress that although ATQ could not be responsibly
 89 incorporated into a mosquito-targeted intervention due to its use as a human prophylactic and
 90 therapeutic drug (23), this compound remains an ideal tool for testing the limits of this strategy, and a
 91 crucial gold standard for screening for novel active compounds.

92 Here we show that *P. falciparum* development is completely blocked when ATQ is delivered, before
 93 infection, to a field-derived *An. coluzzii* population that is highly resistant to pyrethroids, suggesting
 94 that the drug is not detoxified by mosquito pathways inducing insecticide resistance. ATQ is also fully
 95 active against field-derived *P. falciparum* parasites from Burkina Faso. Importantly, mosquito
 96 exposure to this drug completely abrogates development—and therefore transmission—of an
 97 artemisinin-resistant parasite strain from Cambodia, demonstrating the potential of this method to stop
 98 the spread of deleterious parasite mutations. Additionally, ATQ exposure during an ongoing mosquito
 99 infection considerably slows down parasite oocyst growth, reducing the probability of onward
 100 transmission. Finally, we show that delivering ATQ via sugar solutions causes a striking reduction in
 101 both parasite numbers and growth, proving that antimalarials could be incorporated into additional
 102 interventions that target outdoor malaria transmission, such as attractive targeted sugar baits (ATSB).

Targeting *Plasmodium* parasites in the mosquito vector is therefore a promising strategy that circumvents key limitations of current malaria control and preventative interventions.

Results

Exposure to ATQ blocks *P. falciparum* development in insecticide resistant *An. coluzzii*

To determine whether ATQ can abrogate *P. falciparum* development in insecticide resistant mosquitoes, we tested the Bama-R population of *An. coluzzii* (a sibling species to *An. gambiae*) recently colonized from Burkina Faso (Fig. 1). Bama-R mosquitoes are 100% resistant to permethrin at the WHO discriminating concentration (DC, 696 $\mu\text{mol}/\text{m}^2$) and have appreciable acute survival at five times this dose (SFig. 1), likely due to multiple resistance mechanisms as reported in this region (8, 10). Bama-R females were exposed to either glass plates treated with ATQ at the EC₉₉ concentration (100 $\mu\text{mol}/\text{m}^2$, 6 min (19)) or to vehicle-treated plates (control group) immediately preceding infection with *P. falciparum* (NF54), and parasite infection prevalence and intensity were determined at 7 days (d) pIBM. While control females were highly infected, with a median of 12 oocysts per infected midgut and 81.25% overall prevalence of infection, no oocysts were observed in females exposed to ATQ, demonstrating that extant insecticide-resistant mechanisms do not interfere with the antimalarial activity of ATQ (Fig. 1B). These results support the possibility of using mosquito-targeted antimalarials to extend the lifespan of LLINs and IRS, our best malaria control interventions, in regions with widespread insecticide resistance.

Exposure to ATQ abrogates transmission of field-derived *P. falciparum* isolates

We next set out to test the transmission-blocking efficacy of ATQ exposure on a field *P. falciparum* isolate collected from a blood donor (here named P5) from the same region of Burkina Faso where we isolated Bama-R. This isolate (P5) is polyclonal (n=3, determined by PCR genotyping of merozoite surface protein (MSP) 1 (24)), allowing us to test efficacy of treatment against different parasite strains. After a short period in culture, we infected laboratory-reared *An. gambiae* with these parasites and

determined that P5 development was completely blocked in female mosquitoes treated with ATQ (Fig. 1C) such that zero oocysts were observed in mosquito midguts, compared to heavy infections—both in terms of infection intensity (median 59.5 oocysts per midgut) and infection prevalence (95.7%)—in control mosquitoes (G3 colony). Delivery of ATQ to mosquitoes is therefore fully effective against field-derived *P. falciparum* isolates currently circulating in West Africa.

ATQ prevents the transmission of an artemisinin-resistant *P. falciparum* isolate from the GMS

As a next step, we determined whether ATQ exposure could prevent transmission of parasite mutations conferring resistance to frontline human therapeutics. To this end, we used a Cambodian *P. falciparum* patient clone (KH001_029 (7), hereafter ART29) carrying the C580Y mutation in *PfK13* conferring resistance to artemisinin (Fig. 2A). We used the major Asian malaria vector *An. stephensi* for these experiments as initial tests with *An. gambiae* did not produce appreciable infections (SFig. 2). ART29 generated robust infections in control, mock-exposed *An. stephensi*, (median 16 oocysts per midgut, 100% prevalence of infection). However, no oocysts were detected in females exposed to ATQ prior to infection (100 $\mu\text{mol}/\text{m}^2$, 6 min) (Fig. 2B). These data show that mosquito exposure to antimalarials could be an effective strategy for reducing the spread of artemisinin resistance both within and between malaria endemic areas, including sub-Saharan Africa.

ATQ exposure during an ongoing infection delays oocyst growth and decreases sporozoite prevalence

In the field, mosquitoes that contact an antimalarial compound through mosquito-targeted interventions may harbor parasites from a previous blood meal that have already traversed the midgut lumen and formed oocysts. We therefore investigated the effects of ATQ on parasites in which oocyst development is already underway, exposing mosquitoes 6d pIBM (Fig. 3A). In contrast to females exposed before infection, ATQ had no effect on the prevalence or intensity of infection, as measured at 10d pIBM (Fig. 3B). However, we did observe a significant, 45% decrease in the mean oocyst cross-

sectional area (Fig. 3C). Oocyst size is a good proxy for rate of growth (25) and as such, when we sampled mosquitoes a second time at 14 d pIBM, we observed a 33% reduction in the prevalence of sporozoites in the salivary glands of ATQ-treated females (Fig. 3D). Similar results were obtained when ATQ exposure instead occurred at 3 d pIBM (SFig. 3). Taken together, these results suggest that ATQ exposure after oocyst formation has a transient cytostatic effect on *P. falciparum*.

Ingestion of an ATQ-glucose solution blocks the establishment of *P. falciparum* infection

Malaria transmission in the presence of universal effective LLIN coverage, referred to as residual transmission, is driven by mosquitoes that exhibit outdoor or day-time biting preferences, and is a considerable hurdle to malaria eradication efforts (26). Increased focus on residual malaria has stimulated interest in the use of attractive targeted sugar baits (ATSBs) to attract and kill adult mosquitoes irrespective of blood-feeding behavior. In field trials, ATSBs have shown some promise as a tool for suppressing vector populations (27, 28). We therefore assessed whether anti-parasitic compounds in sugar could suppress *Plasmodium* transmission in a similar manner to tarsal exposure to antimalarials (19, 29). We gave *An. gambiae* females access to an ATQ-treated sugar solution (100 μ M ATQ/0.5% v/v DMSO/10% w/v glucose) *ad libitum* for the 24 h preceding *P. falciparum* infection (Fig. 4A). Ingestion of this solution caused a striking 92.4% reduction in parasite prevalence (Fig. 4B). No difference in infection intensity was observed (Control: median = 10.5, ATQ 100 μ M median = 5.5), although this may be underpowered due to the very low number of infected mosquitoes in the ATQ-treated group. Further 10- and 100-fold ATQ dilutions displayed a progressively reduced, dose dependent effect on the prevalence of infection (Fig. 4C).

ATQ ingestion during an ongoing *P. falciparum* infection impairs sporogony

As mosquitoes may often visit an ATSB after acquiring an infectious blood meal, we also investigated the impact of ATQ ingestion on ongoing *P. falciparum* infections, providing ATQ-treated sugar to mosquitoes from 2 d pIBM, when ookinetes have escaped the midgut lumen and formed oocysts on

the midgut basal lamina (Fig. 5A). This time, as we expected a possible cytostatic effect on oocyst growth, we performed a sampling time course to capture oocyst growth through mid- to late sporogony (7d, 10d and 14 d pIBM). We also counted salivary gland sporozoites, the end point of parasite development in the mosquito, at 14 d pIBM. In agreement with our results for post-infection exposure through tarsal contact (Fig. 3), we observed no change in oocyst prevalence and intensity as a result of ATQ ingestion (SFig. 4). However, we observed a striking 80.8% decrease in oocyst cross-sectional area relative to controls at 7 d pIBM, which persisted at later time points (89% and 76.3% decreases at 10- and 14 d pIBM, respectively) (Fig 5B). By 14 d pIBM, ATQ-exposed oocysts had a similar size to 7 d pIBM control oocysts, suggesting a remarkable suppression of growth. Inspection of DAPI-stained infected midguts revealed a stark decrease in the number of nuclear foci, with a single, diffuse DNA signal compared to many condensed foci in oocysts on control-exposed midguts (Fig. 5C). Moreover, despite a robust infection in controls, with a median 3,900 salivary gland sporozoites per mosquito and 77.8% prevalence of infection, we detected no sporozoites in the salivary glands of mosquitoes given access to ATQ-glucose (Fig. 5D). Combined, these data point to a strong suppression of oocyst growth, DNA replication and sporozoite differentiation after ATQ ingestion, suggesting this delivery method would be extremely effective at curbing ongoing infections and transmission.

Discussion

In this study we demonstrate the feasibility of incorporating antimalarials into LLINs, IRS and ATSBs to stop parasite transmission by the *Anopheles* female. Our proof of principle compound ATQ was effective at killing a polyclonal, field-derived parasite isolate from sub-Saharan Africa, showing that an antimalarial-based LLIN or IRS could suppress transmission even in areas of malaria hyperendemicity such as Burkina Faso, where parasite haplotype diversity and complexity of infection are high (30, 31). Crucially, complete transmission-blocking activity was maintained in Bama-R mosquitoes that are highly resistant to insecticides. This recently lab-adapted *An. coluzzii* population was established from an area of Western Burkina Faso where pyrethroid resistance is exceptionally

high (8) due to a combination of mechanisms that include target site mutations (11), cuticular thickening that reduces insecticide penetration (10) and systemic upregulation of metabolic enzymes (cytochrome P450 mono-oxygenases and glutathione-S-transferases) that detoxify the insecticide (12). Both cuticular and metabolic resistance could potentially interfere with drug function by limiting compound uptake and stability, respectively. Our finding that ATQ abolished *P. falciparum* infection despite high insecticide resistance levels (100% of Bama-R mosquitoes survived insecticide exposure in standard WHO bioassays) demonstrates, in principle, that mosquito antimalarial exposure can bypass currently circulating insecticide resistance mechanisms and remain active even in areas where conventional insecticides have ceased to be effective. As our previous work had shown that ATQ exposure had no detrimental effects on female longevity and reproduction, adding anti-parasitic compounds to LLINs or IRS would not only circumvent the emergence of mosquito resistance, but would also potentiate and extend the lifespan of our current best malaria control tools.

Tarsal ATQ exposure also killed artemisinin-resistant *P. falciparum* parasite ART29 in *An. stephensi*. Although these results were somewhat expected given ART29 asexual parasites are ATQ-sensitive *in vitro* (32), they are an important proof of concept that drug-based mosquito-targeted interventions could be developed to specifically contain and eliminate parasite haplotypes conferring resistance to human therapeutics. In this strategy, which we define here as human-mosquito combination therapies, transmission of drug resistant parasites surviving treatment in humans would be prevented through mosquito exposure to antimalarials with distinct and separate modes of action, limiting the consequences of resistance mutations on the broader human population. Importantly, mosquito-targeted antimalarials attack the parasite during an extreme population bottleneck and in a non-cyclical stage in its life cycle (20-22), greatly reducing the probability of selection of both extant and *de novo* resistance mutations compared to treatment during the human asexual cycle. Combined with our previous findings that exposure to ATQ does not impair mosquito fitness (19), the deployment of human-mosquito combination therapies could provide an innovative, integrated approach to apply

drug pressure to parasites across the entirety of their dual host life cycle and stop malaria transmission in endemic regions where current malaria prevention and treatment interventions are faltering.

Ingestion of 100 μ M ATQ/glucose before *P. falciparum* infection blocked transmission in similar manner to tarsal contact, albeit incompletely at this concentration (96% total inhibition compared to 100% killing achieved with tarsal exposure). That parasite inhibition was incomplete could be due to variability in the volume of sugar imbibed or may be a consequence of slow release of ATQ from the crop, a food storage organ in the mosquito foregut from where sugar is gradually transferred to the midgut for digestion (33). The use of mass spectrometry to determine tissue concentrations of ATQ over time after ingestion or tarsal contact may clarify this issue. These results support the use of antimalarials in ATSB-like strategies to reduce residual malaria transmission carried out by mosquitoes that predominantly rest and feed outside and thereby avoid both LLINs and IRS. This concept was originally introduced in the mid 20th century as a way to screen and identify new human therapeutic or prophylactic antimalarial drugs (34-37) and has been sporadically implemented for this purpose in the decades since (reviewed in (38)). However, leveraging this system to suppress malaria transmission in endemic settings has only been recently proposed (19, 29). While current proposed ATSB designs rely on insecticidal ingredients, the use of antimalarials in sugar baits could act as a more specific and environmentally benign paradigm for this promising intervention.

ATQ uptake via tarsal exposure or sugar feeding during oocyst development had an apparent cytostatic effect. A 6-minute tarsal ATQ treatment at 3- or 6-days post infection significantly reduced oocyst growth, resulting in an appreciable reduction in the proportion of salivary gland sporozoite-positive mosquitoes. Taking this effect to its most extreme endpoint, when we provided infected mosquitoes continual access to 100 μ M ATQ-glucose throughout sporogony, no sporozoites were observed by 14 d pIBM. ATQ targets the Qo site of cytochrome b (39), a key element of the mitochondrial electron transport chain with dual roles in both ATP generation through oxidative phosphorylation and DNA replication through ubiquinone-mediated oxidation of dihydroorotate dehydrogenase (40). Thus,

inhibition of either DNA replication or ATP production could explain the cytostatic effect observed here. Consistent with our findings, previous studies have shown that both chemical inhibition of *P. vivax* DNA replication during sporogony (37), and disruption of ATP production through knock-out of components of the tricarboxylic acid cycle in *P. falciparum* (41) and mitochondrial electron transport chain in *P. berghei* (42-44), can cause oocyst arrest. Regardless of the inhibitory mechanism, these results demonstrate that *P. falciparum* can be targeted via LLINs, IRS or ATSB throughout their development in the mosquito. This considerably increases the effective window of opportunity for a mosquito-targeted antimalarial intervention, given that even relatively modest increases in oocyst development time can significantly reduce the probability of parasite transmission due to the short mosquito lifespan (25, 45). Furthermore, slowing or preventing oocyst development could interact synergistically with both the transmission blocking effect of pre-infection antimalarial exposure, and with the life-shortening effects of insecticides.

Although at an early stage, the concept of human-mosquito combination therapies described here has the potential to be an effective element to drive malaria incidence down. To this end, identifying additional compounds with strong antiparasitic activity during the mosquito stages of *P. falciparum* development will be a crucial next step, and one that should leverage the extensive libraries of known antimalarials. Indeed, one of the key strengths of this approach is the potential to exploit and repurpose compounds that are otherwise unsuitable for human therapeutic use, whether due to toxicity, poor bioavailability, poor kinetics or other limiting factors. By integrating human and mosquito-based interventions, this strategy will extend and protect the efficacy of human therapeutics and mosquito interventions, giving malaria control efforts renewed vigor.

Materials and Methods

Mosquito lines, insecticide resistance selection and husbandry

Anopheles spp. mosquito populations used in this study were: 1) *An. gambiae* G3 (“G3”), a highly lab-adapted, insecticide-susceptible strain competent for *P. falciparum* of African origin. 2) *An. stephensi* (Anst-S), a similarly lab-adapted, insecticide-susceptible strain competent for *P. falciparum* of both African and Asian origin received as a gift from The Institute of Molecular Medicine, University of Lisbon, Portugal. 3) *An. gambiae s.l.* Bama-R (“Bama-R”) a colony established through hybridization of the F1 progeny of female *An. coluzzii* collected from Vallee du Kou, Burkina Faso, with our G3 colony. Since establishment, Bama-R has been kept under frequent permethrin selection pressure and exhibits a consistent pyrethroid resistance phenotype. At the time of this study, (F17-20) Bama-R females were highly resistant to pyrethroids, exhibiting 97% survival in standard WHO insecticide resistance assays — briefly, 1 h exposure to the WHO discriminating concentration (DC, 275 mg/m²) of permethrin-impregnated papers with mortality scored at 24 h post-exposure — and 43% survival at 5x the DC. Except for selection of resistance in Bama-R, all mosquito colonies were maintained identically at 26 °C ± 2 °C and 80% ± 10% relative humidity (RH). Larvae were cultured in 2 liter (l) catering pans in 500 ml distilled water (dH₂O) under an optimized density and feeding regimen. At the onset of pupation, pupae were separated from larvae using a vacuum aspirator, collected in dH₂O and placed in a 30x30x30 cm cage (Bugdorm, Megaview Science Co, Ltd, Thailand). After emergence, adult mosquitoes had access to separate sources of 10% glucose (Sigma Aldrich, US) and dH₂O *ad libitum*. For colony maintenance, 5–7-day-old adults were provided a blood meal of donated human blood using an artificial membrane feeding system (Hemotek, UK).

P. falciparum strains culture

294 *P. falciparum* strains used in this study were: 1) *P. falciparum* NF54. NF54 is the drug-susceptible
295 standard strain for mosquito transmission studies, obtained from BEI Resources in 2014. This
296 parasite culture was received through a material transfer agreement (MTA) with the laboratory of Dr.
297 Carolina Barillas-Mury. 2) *P. falciparum* P5. P5 is polyclonal (n=3, KMMM, KMKM, RMMM), as
298 determined by MSP1 PCR genotyping following standard procedures (24), and has been culture-
299 adapted from a blood sample donated by a gametocytemic malaria patient in Burkina Faso in 2017 as
300 part of a previous study. This strain was received through an MTA with Thierry Lefèvre, Institut de
301 Recherche pour le Développement (IRD), Burkina Faso. 3) *P. falciparum* KH001_029 “ART29”.
302 ART29 is a *P. falciparum* monogenomic parasite isolate obtained from an infected human donor in
303 Cambodia between 2011 and 2013 as part of the TRAC I initiative (7). This parasite carries the
304 *PfK13* mutation C580Y associated with resistance to artemisinin. ART29 has clear phenotypic
305 artemisinin resistance, both as determined by *in vivo* clearance time (11.8 h) and *in vitro* ring-stage
306 survival (22.6%) (46), alongside resistance to other antimalarial drugs (but not ATQ) (32). These
307 parasites generate robust infections in *An. stephensi* mosquitoes, but not *An. gambiae* (SFig. 2).
308 For mosquito infection, females were transferred to a secure malaria infection facility and provided a
309 14-21 d post-induction stage V *P. falciparum* gametocyte culture using a custom blown, water heated
310 glass feeder. Within 24 h of infection, partially engorged or unfed mosquitoes were collected by
311 vacuum aspiration and discarded. To determine oocyst burden, between 7 and 14 d pIBM, infected
312 mosquitoes were collected by vacuum aspiration, and dissected to isolate the midgut. The oocyst
313 burden was determined after staining midguts with 0.2% w/v mercurochrome and examination under
314 a 40x air objective inverted compound light microscope (Olympus, US). For sporozoites, at 14 d
315 pIBM infected mosquitoes were collected by vacuum aspiration and beheaded. The mosquito
316 salivary glands were extracted into RPMI media by applying pressure to the lateral thorax. *P.*
317 *falciparum* sporozoites were isolated by homogenization and centrifugation of salivary gland
318 material, followed by resuspension in a known volume of RPMI. Sporozoites were counted using a

disposable haemocytometer under a 20x air objective inverted compound light microscope (Olympus, US). All *P. falciparum* strains were cultured and induced to form gametocytes using standard protocols (47, 48). All strains have been confirmed to be *P. falciparum* by PCR followed by DNA sequencing of the amplified products (49) and have been confirmed free of mycoplasma infection.

Pre- and post-infection tarsal contact infection assays

Tarsal exposure plates were prepared as described previously (19). Briefly, for 100 $\mu\text{mol}/\text{m}^2$ plate concentrations, 0.1 ml of this solution of a 0.1% w/v solution of ATQ in acetone was diluted with 1 ml additional acetone and spread onto a 6 cm diameter (0.002628 m^2) glass petri dish. For 1 mmol/ m^2 , 1 ml of 0.1% w/v ATQ/acetone solution was added directly to the plate. Plates dried for a minimum of 4 h, with agitation on a lateral shaker at room temperature. For pre-infection exposure, 30 min prior to infection, 3-5 d old virgin female mosquitoes were incubated on either ATQ-coated plates, or an acetone treated control, for 6 min. To prevent crowding and agitation, a maximum of 25 mosquitoes were exposed per plate, with all exposures occurring in parallel. For post-infection exposure, due to biosafety considerations, compound exposures were carried out in serial, with a maximum of 10 infected mosquitoes per plate.

Pre- and post-infection sugar feeding infection assays

For experiments involving compound-treated sugar solutions, 20 mM stock solutions of each active ingredient (AI) were prepared in 100% DMSO. Each 20 mM stock solution was diluted 200-fold in 10% w/v glucose to achieve the final working concentration of 100 μM AI/0.5% DMSO/10% w/v glucose. For pre-infection sugar feeding experiments, 2-4 d post-emergence females were denied access to glucose or water for 24 h and then provided access to either the test solution, or a control solution of 0.5% v/v DMSO/10% glucose, for 24 h. After this time had elapsed, all mosquitoes were provided with an infectious *P. falciparum* blood meal as described above. Infected mosquitoes were

provided with untreated 10% w/v glucose *ad libitum* for the remainder of the experiment. For post-infection sugar-feeding experiments, 3-5 d post-emergence female mosquitoes were infected with *P. falciparum* and denied access to glucose or water for 48 h pIBM. After this time, infected mosquitoes were continuously provided either 100 μ M ATQ/0.5% DMSO/10% w/v glucose or 0.5% DMSO/10% w/v glucose as control, *ad libitum*. Sugar feeders were replaced every 48 h for the remainder of the experiment, up to 14 d pIBM.

Statistical analyses

Statistical analyses were carried out using GraphPad Prism v8.4.2 for MacOSX (GraphPad Software Inc., USA) and JMP Pro 14 (SAS Corp. US). For infections, differences in prevalence were analyzed by Chi². In experiments where both treatment groups had individuals that produced >0 oocysts, differences in median oocyst burden between groups (intensity of infection) was analysed using a Mann-Whitney Mean Ranks test. For multiple comparisons, differences in prevalence between multiple groups were determined using pairwise Chi² corrected for multiple comparisons (Bonferroni). Similarly, multiple comparisons of intensity were carried out using Wilcoxon with Dunn's *post hoc*.

Author Contributions:

DGP and FC wrote the manuscript. DGP and FC designed the experiments. DGP carried out statistical analysis. DGP, ASP, EM and NS carried out infection experiments. DFGH, RSY, TL, WRS, SKV, and SB collected, established, maintained, and assayed parasite lines. KAL established and reared insecticide-resistant mosquito lines and carried out resistance assays. TL, AD, RKD, DFW, and FC, provided funding and oversight. All authors read and approved the manuscript prior to submission.

The authors state that they have no conflicting interests.

Figure 1

Figure 1: Exposing *An. gambiae* mosquitoes to ATQ blocks *P. falciparum* development in field-derived parasites and insecticide-resistant mosquitoes. (A) Experimental scheme. (B) Transmission of *P. falciparum* (NF54) is completely blocked when field-derived, highly insecticide-resistant *An. gambiae* (Bama-R) are exposed to ATQ for 6 min to the maximal effective concentration EC₉₉ for insecticide-susceptible mosquitoes. In ATQ-exposed mosquitoes, prevalence (indicated by pie charts) was zero, in contrast to the robust infection in mock-exposed controls (n=160, df=1, $X^2=93.545$, p<0.0001). (C) Similarly, transmission of a polyclonal *P. falciparum* West African patient isolate (P5) was blocked (zero evidence of infection at 7 d pIBM) after *An. gambiae* G3 mosquitoes took an infectious blood meal, despite a strong (prevalence 95.7%, median intensity 59.5 oocysts per midgut) infection in controls (n=187, df=1, $X^2=167.995$, p<0.0001). Median lines and values are indicated, “n” indicates the number of independent samples. Statistical significance is indicated where relevant as follows: ns=not significant, * = p<0.05, **=p<0.01, *=p<0.001, ****=p<0.0001.**

Figure 2

380 **Figure 2: Exposing *An. stephensi* to ATQ blocks an artemisinin-resistant *P. falciparum* patient**
381 **isolate from Cambodia. (A)** Experimental scheme. **(B)** Transmission of artemisinin resistant *P.*
382 *falciparum* (ART29) is completely blocked when *An. stephensi* females (Anst-S) are exposed to ATQ
383 for 6 min to the maximal effective concentration (EC₉₉) for insecticide-susceptible mosquitoes. In
384 ATQ exposed mosquitoes, prevalence (indicated by pie charts) was zero despite robust infection in
385 mock-exposed controls (n=158, df=1, $\chi^2=156$, $p<0.0001$). Median lines and values are indicated, “n”
386 indicates the number of independent samples. Statistical significance is indicated where relevant as
387 follows: ns=not significant, * = $p<0.05$, **= $p<0.01$, ***= $p<0.001$, ****= $p<0.0001$.

Figure 3

388 **Figure 3: Sporozoite prevalence is significantly reduced after ATQ exposure during oocyst**
389 **development. (A)** Experimental scheme. **(B)** There was no effect of 6 d pIBM ATQ exposure on either
390 prevalence (indicated by pie charts) or intensity (indicated by points) of infection determined at 10 d
391 pIBM. Prevalence: $n=136$, $df=1$, $X^2=0.733$, $p=0.3919$, intensity: $n=114$, $df=1$, $U=1482$, $p=0.4335$. **(C)**
392 ATQ exposure at 6 d pIBM significantly reduced the median cross-sectional area of oocysts relative
393 to control ($n=114$, $df=1$, $U=531$, $p<0.0001$). **(D)** The prevalence, but not the median intensity of
394 sporozoites in salivary glands was significantly reduced in mosquitoes exposed to ATQ at 6 d pIBM
395 ($n=125$, $df=1$, $X^2=7.190$, $p=0.0073$). Median lines and values are indicated, “n” indicates the number
396 of independent samples. Statistical significance is indicated where relevant as follows: ns=not
397 significant, * = $p<0.05$, **= $p<0.01$, ***= $p<0.001$, ****= $p<0.0001$.

Figure 4

398 **Figure 4: Ingestion of an ATQ-glucose solution prior to *P. falciparum* infection significantly**
399 **reduces transmission. (A)** Experimental scheme. **(B)** Ingestion of 100 μ M ATQ/0.5% DMSO/10%
400 w/v glucose significantly reduced the prevalence of infection at 7 d pIBM (n=318, df=1, $X^2=162.467$,
401 $p<0.0001$) but had no detectable effect on the median intensity of infection (n=128, df=1, $U=480.5$,
402 $p=0.3364$). **(C)** Significant, dose-dependent inhibition of oocyst prevalence was observed with a 10-
403 fold reduction in ATQ concentration (10 μ M: n=134, df=1, $X^2=19.275$, $p<0.0001$). A non-significant
404 reduction in prevalence was also observed at 1 μ M (n=141, df=1, $X^2=2.642$, $p=0.1041$). Median lines
405 and values are indicated, “n” indicates the number of independent samples. Statistical significance is
406 indicated where relevant as follows: ns=not significant, * = $p<0.05$, **= $p<0.01$, ***= $p<0.001$,
407 ****= $p<0.0001$.

Figure 5

Figure 5: Ingestion of ATQ-glucose after *P. falciparum* infection significantly blocks parasite development. (A) Experimental scheme. (B) Oocyst size over time. Access to ATQ-glucose from 2 d pIBM caused a significant reduction in oocyst cross-sectional area (“size”) relative to control at 7 d pIBM (n=69, df=1, $t=13.63$, $p<0.0001$), 10 d pIBM (n=70, df=1, $t=8.998$, $p<0.001$), and 14 d pIBM (n=61, df=1, $t=8.793$, $p<0.0001$). Means are indicated, error bars represent the standard error of the mean (SEM). (C) Example brightfield, and fluorescent micrographs of control and ATQ-exposed bright-field and DAPI-stained oocysts at 10 d pIBM (outline indicated by dashed line). At this timepoint, the control oocyst is large, and contains many discrete nuclear foci, indicating nuclear division and sporozoite differentiation. In contrast, the ATQ-exposed oocyst is small relative to control and contains a single nuclear focus. Dense hemozoin crystals (white triangle), typically associated with younger oocysts, are visible. Scale bars represent 10 μm . (D) Salivary gland sporozoite prevalence and intensity at 14 d pIBM. No sporozoites (0% prevalence, median intensity = 0) were observed in salivary glands samples collected from mosquitoes given access to 100 μM ATQ/0.5% DMSO/10% w/v glucose *ad libitum* (n=86, df=1, $X^2=53.202$, $p<0.0001$). Where relevant, median lines and values are indicated, “n” indicates the number of independent samples. Statistical significance is indicated where relevant as follows: ns=not significant, * = $p<0.05$, **= $p<0.01$, ***= $p<0.001$, ****= $p<0.0001$.

Supplementary Figure 1

424 **Supplementary Figure 1: *An. gambiae* Bama-R mosquitoes are highly resistant to permethrin.**

425 **(A)** Experimental scheme. **(B)** G3 females were 0% resistant at the DC, while 97% of exposed Bama-

426 R females survived at the same dose, and 43% survived exposure to 5xDC, indicating extreme

427 permethrin resistance. Mean survival $\pm$ SEM from 3 replicates is indicated.

Supplementary Figure 2

428 **Supplementary Figure 2: Development of the artemisinin-resistant *P. falciparum* parasite**
 429 **ART29 in *An. stephensi* and *An. gambiae*.** Female G3 (*An. gambiae*) and Anst (*An. stephensi*) were
 430 provided with a blood meal containing mature ART29 gametocytes. Outcome of infection was
 431 determined at 7 d pIBM by oocyst count. While ART29 exhibited poor infectivity in *An. gambiae*
 432 (23.8% infection prevalence), they established robust infections in *An. stephensi* (100% infection
 433 prevalence).

Supplementary Figure 3

434 **Supplementary Figure 3: The proportion of *An. gambiae* mosquitoes with salivary gland**
 435 **sporozoites is significantly reduced after mosquito ATQ exposure at 3 d pIBM. (A)** Experimental
 436 scheme. **(B)** There was no effect of 3 d pIBM ATQ exposure on either prevalence (indicated by pie
 437 charts) or intensity (indicated by points) of infection determined at 10 d pIBM. Prevalence: n=95, df=1,
 438 $\chi^2=0.540$, p=0.4623, intensity: n=80, df=1, U=717.5, p=0.4530. **(C)** ATQ exposure at 3 d pIBM
 439 significantly reduced the median cross-sectional area of oocysts at 7 d pIBM relative to control (n=50,
 440 df=1, U=110, p<0.0001). **(D)** The prevalence, but not the median intensity of *P. falciparum* sporozoites
 441 in mosquito salivary glands was significantly reduced in mosquitoes exposed to ATQ at 3 d pIBM
 442 (n=144, df=1, $\chi^2=9.995$, p=0.0016). Median lines and values are indicated, “n” indicates the number
 443 of independent samples. Statistical significance is indicated where relevant as follows: ns=not
 444 significant, * = p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001.

Supplementary Figure 4

445 **Supplementary Figure 4: Ingestion of an ATQ-glucose solution after *P. falciparum* infection has**
 446 **no effect on oocyst prevalence or intensity.** There was no difference relative to controls in either
 447 intensity (n=68, df=1, $U=495.5$, $p=0.3257$) or prevalence (n=81, df=1, $\chi^2=2.441$, $p=0.1182$) of oocysts
 448 at 10 d pIBM in females with continued access to 100 μ M ATQ/0.5% DMSO/10% w/v glucose from
 449 2 d pIBM - 14 d pIBM. Median lines and values are indicated, “n” indicates the number of independent
 450 samples. Statistical significance is indicated where relevant as follows: ns=not significant, * = $p<0.05$,
 451 **= $p<0.01$, ***= $p<0.001$, ****= $p<0.0001$.

References

1. World Malaria Report 2020. World Health Organisation. 2020.
2. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, Battle K, Moyes CL, Henry A, Eckhoff PA, Wenger EA, Briet O, Penny MA, Smith TA, Bennett A, Yukich J, Eisele TP, Griffin JT, Fergus CA, Lynch M, Lindgren F, Cohen JM, Murray CLJ, Smith DL, Hay SI, Cibulskis RE, Gething PW. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature*. 2015;526(7572):207-11. doi: 10.1038/nature15535. PubMed PMID: 26375008; PMCID: PMC4820050.
3. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-Resistant Malaria: The Era of ACT. *Curr Infect Dis Rep*. 2010;12(3):165-73. Epub 2011/02/11. doi: 10.1007/s11908-010-0099-y. PubMed PMID: 21308525; PMCID: PMC3058555.
4. Ogbonna A, Uneke CJ. Artemisinin-based combination therapy for uncomplicated malaria in sub-Saharan Africa: the efficacy, safety, resistance and policy implementation since Abuja 2000. *Trans R Soc Trop Med Hyg*. 2008;102(7):621-7. Epub 2008/05/24. doi: 10.1016/j.trstmh.2008.03.024. PubMed PMID: 18499204.
5. Staedke SG, Gonahasa S, Dorsey G, Kanya MR, Maiteki-Sebuguzi C, Lynd A, Katureebe A, Kyohere M, Mutungi P, Kigozi SP, Opigo J, Hemingway J, Donnelly MJ. Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a national LLIN distribution campaign. *Lancet*. 2020;395(10232):1292-303. Epub 2020/04/20. doi: 10.1016/S0140-6736(20)30214-2. PubMed PMID: 32305094; PMCID: PMC7181182.
6. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R, Blessborn D, Song L, Tullo GS, Fay MP, Anderson JM, Tarning J, Fairhurst RM. Dihydroartemisinin-piperaquine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *The Lancet Infectious diseases*. 2016;16(3):357-65. doi: 10.1016/S1473-3099(15)00487-9. PubMed PMID: 26774243; PMCID: 4792715.
7. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroeth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han KT, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ, Tracking Resistance to Artemisinin C. Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2014;371(5):411-23. Epub 2014/07/31. doi: 10.1056/NEJMoa1314981. PubMed PMID: 25075834; PMCID: PMC4143591.
8. Toé KH, Jones CM, N'Fale S, Ismail HM, Dabiré RK, Ranson H. Increased Pyrethroid Resistance in Malaria Vectors and Decreased Bed Net Effectiveness, Burkina Faso. *Emerging Infectious Diseases*. 2014;20(10):1691-6. doi: 10.3201/eid2010.140619. PubMed PMID: PMC4193182.
9. Samantsidis GR, Panteleri R, Denecke S, Kounadi S, Christou I, Nauen R, Douris V, Vontas J. 'What I cannot create, I do not understand': functionally validated synergism of metabolic and target site insecticide resistance. *Proc Biol Sci*. 2020;287(1927):20200838. Epub 2020/05/27. doi: 10.1098/rspb.2020.0838. PubMed PMID: 32453986; PMCID: PMC7287358.
10. Balabanidou V, Kampouraki A, MacLean M, Blomquist GJ, Tittiger C, Juarez MP, Mijailovsky SJ, Chalepakakis G, Anthousi A, Lynd A, Antoine S, Hemingway J, Ranson H, Lycett GJ, Vontas J. Cytochrome P450 associated with insecticide resistance catalyzes cuticular hydrocarbon production in *Anopheles gambiae*. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113(33):9268-73. doi: 10.1073/pnas.1608295113. PubMed PMID: 27439866; PMCID: PMC4995928.
11. Ranson H, Jensen B, Vulule JM, Wang X, Hemingway J, Collins FH. Identification of a point mutation in the voltage-gated sodium channel gene of Kenyan *Anopheles gambiae* associated with resistance to DDT and

- pyrethroids. *Insect Mol Biol.* 2000;9(5):491-7. Epub 2000/10/13. doi: 10.1046/j.1365-2583.2000.00209.x. PubMed PMID: 11029667.
12. Stevenson BJ, Bibby J, Pignatelli P, Muangnoicharoen S, O'Neill PM, Lian LY, Muller P, Nikou D, Steven A, Hemingway J, Sutcliffe MJ, Paine MJ. Cytochrome P450 6M2 from the malaria vector *Anopheles gambiae* metabolizes pyrethroids: Sequential metabolism of deltamethrin revealed. *Insect Biochem Mol Biol.* 2011;41(7):492-502. Epub 2011/02/18. doi: 10.1016/j.ibmb.2011.02.003. PubMed PMID: 21324359.
13. World Health Organization. Regional Office for the Western P. Containment of Malaria Multi-drug Resistance on the Cambodia-Thailand Border, Phnom Penh, 29-30 January 2007 : report of an Informal Consultation. New Delhi : WHO Regional Office for South-East Asia; 2007.
14. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Menard D. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. *Nature.* 2014;505(7481):50-5. Epub 2013/12/20. doi: 10.1038/nature12876. PubMed PMID: 24352242; PMCID: PMC5007947.
15. Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, Smithuis FM, Hlaing TM, Tun KM, van der Pluijm RW, Tripura R, Miotto O, Menard D, Dhorda M, Day NPJ, White NJ, Dondorp AM. The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study. *The Lancet Infectious diseases.* 2017;17(5):491-7. Epub 2017/02/06. doi: 10.1016/S1473-3099(17)30048-8. PubMed PMID: 28161569; PMCID: PMC5406483.
16. Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible *falciparum* malaria in Southeast of Tanzania. *Sci Rep.* 2020;10(1):3500. Epub 2020/02/28. doi: 10.1038/s41598-020-60549-7. PubMed PMID: 32103124; PMCID: PMC7044163.
17. Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, Sendegaya A, Gahutu JB, Mockenhaupt FP. Artemisinin Resistance-Associated K13 Polymorphisms of *Plasmodium falciparum* in Southern Rwanda, 2010-2015. *Am J Trop Med Hyg.* 2016;95(5):1090-3. Epub 2016/11/04. doi: 10.4269/ajtmh.16-0483. PubMed PMID: 27573632; PMCID: PMC5094222.
18. Sinka ME, Pironon S, Massey NC, Longbottom J, Hemingway J, Moyes CL, Willis KJ. A new malaria vector in Africa: Predicting the expansion range of *Anopheles stephensi* and identifying the urban populations at risk. *Proceedings of the National Academy of Sciences of the United States of America.* 2020;117(40):24900-8. Epub 2020/09/16. doi: 10.1073/pnas.2003976117. PubMed PMID: 32929020; PMCID: PMC7547157.
19. Paton DG, Childs LM, Itoe MA, Holmdahl IE, Buckee CO, Catteruccia F. Exposing *Anopheles* mosquitoes to antimalarials blocks *Plasmodium* parasite transmission. *Nature.* 2019;567(7747):239-43. Epub 2019/03/01. doi: 10.1038/s41586-019-0973-1. PubMed PMID: 30814727.
20. Graumans W, Jacobs E, Bousema T, Sinnis P. When Is a *Plasmodium*-Infected Mosquito an Infectious Mosquito? *Trends Parasitol.* 2020;36(8):705-16. doi: 10.1016/j.pt.2020.05.011. PubMed PMID: 32620501; PMCID: PMC7386819.
21. Smith RC, Vega-Rodriguez J, Jacobs-Lorena M. The *Plasmodium* bottleneck: malaria parasite losses in the mosquito vector. *Mem Inst Oswaldo Cruz.* 2014;109(5):644-61. PubMed PMID: 25185005; PMCID: PMC4156458.
22. Sinden RE, Billingsley PF. *Plasmodium* invasion of mosquito cells: hawk or dove? *Trends Parasitol.* 2001;17(5):209-12. doi: 10.1016/s1471-4922(01)01928-6. PubMed PMID: 11323288.
23. Burrows J, Fidock DA, Miller RS, Rees S. Blocking *Plasmodium* Development in Mosquitoes: A Powerful New Approach for Expanding Malaria Control Efforts. *Am J Trop Med Hyg.* 2019;101(4):734-5. Epub 2019/07/03. doi: 10.4269/ajtmh.19-0318. PubMed PMID: 31264564; PMCID: PMC6779223.
24. Kaneko O, Kimura M, Kawamoto F, Ferreira MU, Tanabe K. *Plasmodium falciparum*: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. *Exp Parasitol.* 1997;86(1):45-57. doi: 10.1006/expr.1997.4147. PubMed PMID: 9149240.
25. Shaw WR, Holmdahl IE, Itoe MA, Werling K, Marquette M, Paton DG, Singh N, Buckee CO, Childs LM, Catteruccia F. Multiple blood feeding in mosquitoes shortens the *Plasmodium falciparum* incubation period

and increases malaria transmission potential. *PLoS Pathog.* 2020;16(12):e1009131. Epub 2021/01/01. doi: 10.1371/journal.ppat.1009131. PubMed PMID: 33382824; PMCID: PMC7774842.

26. Sherrard-Smith E, Sarp JE, Beale AD, Fornadel C, Norris LC, Moore SJ, Mihreteab S, Charlwood JD, Bhatt S, Winskill P, Griffin JT, Churcher TS. Mosquito feeding behavior and how it influences residual malaria transmission across Africa. *Proceedings of the National Academy of Sciences of the United States of America.* 2019;116(30):15086-95. Epub 2019/07/10. doi: 10.1073/pnas.1820646116. PubMed PMID: 31285346; PMCID: PMC6660788.

27. Muller GC, Beier JC, Traore SF, Toure MB, Traore MM, Bah S, Doumbia S, Schlein Y. Successful field trial of attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the *Anopheles gambiae* complex in Mali, West Africa. *Malar J.* 2010;9:210. Epub 2010/07/29. doi: 10.1186/1475-2875-9-210. PubMed PMID: 20663142; PMCID: PMC2914067.

28. Beier JC, Muller GC, Gu W, Arheart KL, Schlein Y. Attractive toxic sugar bait (ATSB) methods decimate populations of *Anopheles* malaria vectors in arid environments regardless of the local availability of favoured sugar-source blossoms. *Malar J.* 2012;11:31. doi: 10.1186/1475-2875-11-31. PubMed PMID: 22297155; PMCID: PMC3293779.

29. Paaijmans K, Fernandez-Busquets X. Antimalarial drug delivery to the mosquito: an option worth exploring? *Future Microbiol.* 2014;9(5):579-82. doi: 10.2217/fmb.14.30. PubMed PMID: 24957084.

30. Soulama I, Nebie I, Ouedraogo A, Gansane A, Diarra A, Tiono AB, Bougouma EC, Konate AT, Kabre GB, Taylor WR, Sirima SB. *Plasmodium falciparum* genotypes diversity in symptomatic malaria of children living in an urban and a rural setting in Burkina Faso. *Malar J.* 2009;8:135. Epub 2009/06/24. doi: 10.1186/1475-2875-8-135. PubMed PMID: 19545390; PMCID: PMC2705376.

31. Sondo P, Derra K, Rouamba T, Nakanabo Diallo S, Taconet P, Kazienga A, Ilboudo H, Tahita MC, Valea I, Sorgho H, Lefevre T, Tinto H. Determinants of *Plasmodium falciparum* multiplicity of infection and genetic diversity in Burkina Faso. *Parasit Vectors.* 2020;13(1):427. Epub 2020/08/21. doi: 10.1186/s13071-020-04302-z. PubMed PMID: 32819420; PMCID: PMC7441709.

32. Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, Amaratunga C, Woodrow CJ, Ashley EA, White NJ, Dondorp AM, Fairhurst RM, Arie F, Menard D, Wirth DF, Volkman SK. Plasmepsin II-III copy number accounts for bimodal piperazine resistance among Cambodian *Plasmodium falciparum*. *Nat Commun.* 2018;9(1):1769. Epub 2018/05/04. doi: 10.1038/s41467-018-04104-z. PubMed PMID: 29720620; PMCID: PMC5931971.

33. Kessler S, Vlimant M, Guerin PM. The sugar meal of the African malaria mosquito *Anopheles gambiae* and how deterrent compounds interfere with it: a behavioural and neurophysiological study. *J Exp Biol.* 2013;216(Pt 7):1292-306. Epub 2012/12/25. doi: 10.1242/jeb.076588. PubMed PMID: 23264482.

34. Terzian LA, Weathersby AB. The action of antimalarial drugs in mosquitoes infected with *Plasmodium falciparum*. *Am J Trop Med Hyg.* 1949;29(1):19-22. PubMed PMID: 18110329.

35. Terzian LA, Ward PA, Stahler N. A new criterion for the selection of compounds for curative activity in *Plasmodium vivax* malaria. *Am J Trop Med Hyg.* 1951;31(6):692-7. doi: 10.4269/ajtmh.1951.s1-31.692. PubMed PMID: 14894754.

36. Terzian LA, Stahler N, Ward PA. The effect of antibiotics and metabolites on the immunity of mosquitoes to malarial infection. *J Infect Dis.* 1952;90(2):116-30. doi: 10.1093/infdis/90.2.116. PubMed PMID: 14917887.

37. Terzian LA, Stahler N, Dawkins AT, Jr. The sporogony of *Plasmodium vivax* in *Anopheles* mosquitoes as a system for evaluating the prophylactic and curative capabilities of potential antimalarial compounds. *Exp Parasitol.* 1968;23(1):56-66. doi: 10.1016/0014-4894(68)90042-8. PubMed PMID: 4876903.

38. Butcher GA. Antimalarial drugs and the mosquito transmission of *Plasmodium*. *Int J Parasitol.* 1997;27(9):975-87. doi: 10.1016/s0020-7519(97)00079-9. PubMed PMID: 9363480.

39. Srivastava IK, Rottenberg H, Vaidya AB. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. *J Biol Chem.* 1997;272(7):3961-6. PubMed PMID: 9020100.

40. Painter HJ, Morrissey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage *Plasmodium falciparum*. *Nature*. 2007;446(7131):88-91. doi: 10.1038/nature05572. PubMed PMID: 17330044.
41. Ke H, Lewis IA, Morrissey JM, McLean KJ, Ganesan SM, Painter HJ, Mather MW, Jacobs-Lorena M, Llinas M, Vaidya AB. Genetic investigation of tricarboxylic acid metabolism during the *Plasmodium falciparum* life cycle. *Cell Rep*. 2015;11(1):164-74. doi: 10.1016/j.celrep.2015.03.011. PubMed PMID: 25843709; PMCID: PMC4394047.
42. Boysen KE, Matuschewski K. Arrested oocyst maturation in *Plasmodium* parasites lacking type II NADH:ubiquinone dehydrogenase. *J Biol Chem*. 2011;286(37):32661-71. doi: 10.1074/jbc.M111.269399. PubMed PMID: 21771793; PMCID: PMC3173203.
43. Hino A, Hirai M, Tanaka TQ, Watanabe Y, Matsuoka H, Kita K. Critical roles of the mitochondrial complex II in oocyst formation of rodent malaria parasite *Plasmodium berghei*. *J Biochem*. 2012;152(3):259-68. doi: 10.1093/jb/mvs058. PubMed PMID: 22628552.
44. Sturm A, Mollard V, Cozijnsen A, Goodman CD, McFadden GI. Mitochondrial ATP synthase is dispensable in blood-stage *Plasmodium berghei* rodent malaria but essential in the mosquito phase. *Proc Natl Acad Sci U S A*. 2015;112(33):10216-23. doi: 10.1073/pnas.1423959112. PubMed PMID: 25831536; PMCID: PMC4547259.
45. Werling K, Shaw WR, Itoe MA, Westervelt KA, Marcenac P, Paton DG, Peng D, Singh N, Smidler AL, South A, Deik AA, Mancio-Silva L, Demas AR, March S, Calvo E, Bhatia SN, Clish CB, Catteruccia F. Steroid hormone function controls non-competitive *Plasmodium* development in *Anopheles*. *Cell*. 2019;(in press).
46. Mukherjee A, Bopp S, Magistrado P, Wong W, Daniels R, Demas A, Schaffner S, Amaratunga C, Lim P, Dhorda M, Miotto O, Woodrow C, Ashley EA, Dondorp AM, White NJ, Wirth D, Fairhurst R, Volkman SK. Artemisinin resistance without pfkelch13 mutations in *Plasmodium falciparum* isolates from Cambodia. *Malar J*. 2017;16(1):195. Epub 2017/05/13. doi: 10.1186/s12936-017-1845-5. PubMed PMID: 28494763; PMCID: PMC5427620.
47. Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science*. 1976;193(4254):673-5. Epub 1976/08/20. doi: 10.1126/science.781840. PubMed PMID: 781840.
48. Ifediba T, Vanderberg JP. Complete in vitro maturation of *Plasmodium falciparum* gametocytes. *Nature*. 1981;294(5839):364-6. Epub 1981/11/26. PubMed PMID: 7031476.
49. Snounou G, Viriyakosol S, Zhu XP, Jarra W, Pinheiro L, do Rosario VE, Thaithong S, Brown KN. High sensitivity of detection of human malaria parasites by the use of nested polymerase chain reaction. *Mol Biochem Parasitol*. 1993;61(2):315-20. PubMed PMID: 8264734.